Compare IDN & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDN | PLRX |
|---|---|---|
| Founded | 1994 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.5M | 74.9M |
| IPO Year | 2014 | 2020 |
| Metric | IDN | PLRX |
|---|---|---|
| Price | $4.35 | $1.14 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 4 |
| Target Price | ★ $7.33 | $2.67 |
| AVG Volume (30 Days) | 363.4K | ★ 449.3K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 220.00 | 29.97 |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $4,433,454.00 | N/A |
| Revenue This Year | $12.54 | N/A |
| Revenue Next Year | $15.32 | N/A |
| P/E Ratio | $135.00 | ★ N/A |
| Revenue Growth | ★ 23.21 | N/A |
| 52 Week Low | $3.95 | $1.09 |
| 52 Week High | $9.08 | $1.95 |
| Indicator | IDN | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.56 | 38.25 |
| Support Level | $3.99 | N/A |
| Resistance Level | $4.56 | $1.37 |
| Average True Range (ATR) | 0.21 | 0.05 |
| MACD | 0.12 | -0.00 |
| Stochastic Oscillator | 97.56 | 10.00 |
Intellicheck Inc is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification. The group delivers on-demand digital and physical identity verification solutions for KYC, AML, fraud prevention, and age verification needs. The products of the company includes solutions for preventing identity fraud across any industry delivered via smartphone, tablet, POS integration or other electronic devices.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.